Analysts expect Aytu Biopharma, Inc to report revenue of 13.15 M for Q1 27, against a range of 12.12 M to 14.18 M. The most recent reported quarter, Q4 26, came in at 16.11 M, a 24.9% beat against the 12.89 M consensus.
| Metric | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 16.57 M | 16.22 M | 18.45 M | 15.13 M | 13.89 M | 15.20 M | 12.41 M | 16.11 M | - | - | - | - | - | - | - | - | ||||||||
| High Estimate | 14.05 M | 15.84 M | 15.91 M | 19.49 M | 13.57 M | 13.97 M | 13.95 M | 13.62 M | 14.18 M | 16.18 M | 19.78 M | 24.20 M | 19.02 M | 20.89 M | 25.56 M | 31.02 M | ||||||||
| Low Estimate | 12.48 M | 13.59 M | 13.35 M | 17.42 M | 12.27 M | 11.99 M | 11.80 M | 12.17 M | 12.12 M | 13.48 M | 18.22 M | 20.63 M | 16.10 M | 18.52 M | 22.26 M | 29.08 M | ||||||||
| Consensus Estimate | 13.27 M | 14.71 M | 14.63 M | 18.45 M | 12.92 M | 12.98 M | 12.88 M | 12.89 M | 13.15 M | 14.83 M | 19.00 M | 22.42 M | 17.56 M | 19.70 M | 23.91 M | 30.05 M |
Analysts expect Aytu Biopharma, Inc to report earnings per share of -0.32 for Q1 27, against a range of -0.33 to -0.31. The most recent reported quarter, Q4 26, came in at 0.00, a 100.0% beat against the -0.27 consensus.
| Metric | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.20 | -0.28 | 0.20 | -2.93 | -0.08 | -1.05 | -0.53 | 0.00 | - | - | - | - | - | - | - | - | ||||||||
| High Estimate | -0.33 | -0.25 | -0.15 | -0.03 | -0.17 | -0.37 | -0.43 | -0.26 | -0.31 | -0.24 | -0.17 | -0.09 | 0.33 | -0.06 | 0.08 | 0.02 | ||||||||
| Low Estimate | -0.39 | -0.27 | -0.17 | -0.03 | -0.19 | -0.41 | -0.47 | -0.28 | -0.33 | -0.26 | -0.19 | -0.09 | 0.29 | -0.08 | 0.06 | 0.02 | ||||||||
| Consensus Estimate | -0.36 | -0.26 | -0.16 | -0.03 | -0.18 | -0.39 | -0.45 | -0.27 | -0.32 | -0.25 | -0.18 | -0.09 | 0.31 | -0.07 | 0.07 | 0.02 |
Pull Wall Street consensus for Aytu Biopharma, Inc (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AYTU&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AYTU", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AYTU&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();